Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552461 · ClinicalTrials.gov registry record · Phase 2
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
A Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00552461 is a Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease that has completed, run by East Carolina University. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00552461, a Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
Conditions Studied
Interventions
- DRUG rituximab
Study Locations (1)
North Carolina
- East Carolina University - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552461
The ClinicalTrials.gov registry entry for NCT00552461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Alveolar Proteinosis appearing as the primary indexed condition, and to 1 intervention - of which rituximab is the first listed.
NCT00552461 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00552461 about?
NCT00552461 is a clinical study titled "Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis". The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
What is the current status of trial NCT00552461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-01. Estimated completion is 2011-12.
What conditions does trial NCT00552461 study?
This clinical trial studies the following conditions: Pulmonary Alveolar Proteinosis, Primary Disease.
What interventions are being tested in trial NCT00552461?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00552461?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552461 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Alveolar Proteinosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.